Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Role of Natural Products As Pcsk9 Modulators: A Review Publisher Pubmed



Khayatan D1, 2 ; Zare K3 ; Khanahmadi M1, 2 ; Momtaz S4, 5 ; Butler AE6 ; Jamialahmadi T7, 8 ; Almahmeed W9 ; Abdolghaffari AH1, 2 ; Sahebkar A10, 11, 12
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
  2. 2. GI Pharmacology Interest Group (GPIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran
  3. 3. School of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran
  4. 4. Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Tehran, Iran
  5. 5. Department of Toxicology and Pharmacology, School of Pharmacy, and Toxicology and Diseases Group, Pharmaceutical Sciences Research Center (PSRC), The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Royal College of Surgeons in Ireland Bahrain, Adliya, Bahrain
  7. 7. Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
  8. 8. Medical Toxicology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
  9. 9. Heart and Vascular Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
  10. 10. Center for Global Health Research, Saveetha Medical College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India
  11. 11. Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
  12. 12. Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

Source: Phytotherapy Research Published:2024


Abstract

A variety of mechanisms and drugs have been shown to attenuate cardiovascular disease (CVD) onset and/or progression. Recent researchers have identified a potential role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in modulating lipid metabolism and reducing plasma low density lipoprotein (LDL) levels. PCSK9 is the central protein in the metabolism of LDL cholesterol (LDL-C) owing to its major function in LDL receptor (LDLR) degradation. Due to the close correlation of cardiovascular disease with lipid levels, many in vivo and in vitro investigations are currently underway studying the physiological role of PCSK9. Furthermore, many studies are actively investigating the mechanisms of various compounds that influence lipid associated-disorders and their associated cardiovascular diseases. PCSK9 inhibitors have been shown to have significant impact in the prevention of emerging cardiovascular diseases. Natural products can effectively be used as PCSK9 inhibitors to control lipid levels through various mechanisms. In this review, we evaluate the role of phytochemicals and natural products in the regulation of PCSK9, and their ability to prevent cardiovascular diseases. Moreover, we describe their mechanisms of action, which have not to date been delineated. © 2024 John Wiley & Sons Ltd.
Other Related Docs
10. Traditional Medicine and Natural Products As Antiparasitic Agents, Advances in Antiparasitic Therapies and Drug Delivery (2023)
14. Harnessing Therapeutic Potentials of Statins Using Nanofibrous Carriers, Bioinorganic Chemistry and Applications (2021)
27. Neuroprotective Agents in the Intensive Care Unit, Journal of Pharmacopuncture (2018)
28. Implications on the Therapeutic Potential of Statins Via Modulation of Autophagy, Oxidative Medicine and Cellular Longevity (2021)
31. Effects of Statins on Renin–Angiotensin System, Journal of Cardiovascular Development and Disease (2021)
38. Statins: Beneficial Effects in Treatment of Covid-19, Advances in Experimental Medicine and Biology (2023)
47. Protective Effects of Curcumin Against Traumatic Brain Injury, Biomedicine and Pharmacotherapy (2022)